{"id":25324,"date":"2022-09-29T12:35:00","date_gmt":"2022-09-29T04:35:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25324"},"modified":"2025-02-04T12:42:01","modified_gmt":"2025-02-04T04:42:01","slug":"simcere-grants-almirall-global-rights-to-autoimmune-drug-sim0278","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25324","title":{"rendered":"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278"},"content":{"rendered":"\n

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096<\/a>) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM<\/a>), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront fee of $15 million and is committed to $492 million in development and commercialization milestone payments, along with low-teen commissions based on future sales.<\/p>\n\n\n\n

SIM0278: Drug Overview<\/strong>
SIM0278 is a regulatory T cell (Treg)-preferred IL2 fusion protein (IL-2 mu-Fc) based on Simcere’s proprietary protein engineering technology platform. The drug is designed for subcutaneous administration to treat multiple autoimmune diseases. Preclinical studies have shown that SIM0278 has significantly optimized pharmacokinetic (PK) properties and can selectively activate Treg cells without activating effector T cells or NK cells, thereby restoring the immune balance of the body. The drug is currently ready for Investigational New Drug (IND) filing.<\/p>\n\n\n\n

Partnership and Future Outlook<\/strong>
This strategic partnership underscores Simcere’s commitment to advancing innovative therapies for autoimmune diseases on a global scale. By leveraging Almirall’s expertise in development and commercialization, the collaboration aims to accelerate the clinical development and market entry of SIM0278, ultimately benefiting patients with autoimmune conditions worldwide.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2098,65,30,2466,1099,271],"class_list":["post-25324","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-almirall","tag-auto-immune","tag-biotech","tag-bme-alm","tag-hkg-2096","tag-simcere-pharmaceutical"],"yoast_head":"\nSimcere Grants Almirall Global Rights to Autoimmune Drug SIM0278 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront fee of $15 million and is committed to $492 million in development and commercialization milestone payments, along with low-teen commissions based on future sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25324\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25324\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T04:35:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-04T04:42:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25324#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25324\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278\",\"datePublished\":\"2022-09-29T04:35:00+00:00\",\"dateModified\":\"2025-02-04T04:42:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25324\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Almirall\",\"Auto-immune\",\"Biotech\",\"BME: ALM\",\"HKG: 2096\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25324#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25324\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25324\",\"name\":\"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-29T04:35:00+00:00\",\"dateModified\":\"2025-02-04T04:42:01+00:00\",\"description\":\"China's Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront fee of $15 million and is committed to $492 million in development and commercialization milestone payments, along with low-teen commissions based on future sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25324#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25324\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25324#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278 - Insight, China's Pharmaceutical Industry","description":"China's Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront fee of $15 million and is committed to $492 million in development and commercialization milestone payments, along with low-teen commissions based on future sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25324","og_locale":"en_US","og_type":"article","og_title":"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25324","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-29T04:35:00+00:00","article_modified_time":"2025-02-04T04:42:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25324#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25324"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278","datePublished":"2022-09-29T04:35:00+00:00","dateModified":"2025-02-04T04:42:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25324"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Almirall","Auto-immune","Biotech","BME: ALM","HKG: 2096","Simcere Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25324#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25324","url":"https:\/\/flcube.com\/?p=25324","name":"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-29T04:35:00+00:00","dateModified":"2025-02-04T04:42:01+00:00","description":"China's Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with Spain-based Almirall S.A. (BME: ALM), granting Almirall exclusive development and commercialization rights to the autoimmune disease drug candidate SIM0278 outside of Greater China. Under the terms of the deal, Almirall will pay Simcere an upfront fee of $15 million and is committed to $492 million in development and commercialization milestone payments, along with low-teen commissions based on future sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25324#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25324"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25324#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25324"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25324\/revisions"}],"predecessor-version":[{"id":25326,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25324\/revisions\/25326"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}